Effects of Ramelteon and Other Sleep-Promoting Drugs on Serum Low-Density Lipoprotein and Non-high-density Lipoprotein Cholesterol: A Retrospective Comparative Pilot Study
| Autor: | Daisuke Yasuda, Yurina Omiya, Noriaki Kume, Rumiko Shimizu, Miwa Yamamoto, Yuriko Tanizaki, Sayaka Kamiike, Tohru Hashida, Yoshinori Hiraoka, Haruki Torii |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_treatment Lipoproteins Ramelteon Pharmaceutical Science Pilot Projects 030204 cardiovascular system & hematology Pharmacology Medical Records Melatonin 03 medical and health sciences 0302 clinical medicine medicine Humans Circadian rhythm Melatonin receptor agonist Dialysis Aged Retrospective Studies business.industry Receptor Melatonin MT2 Receptor Melatonin MT1 Lipid metabolism General Medicine Middle Aged medicine.disease Lipoproteins LDL Cholesterol Indenes Sleep Aids Pharmaceutical lipids (amino acids peptides and proteins) Female business 030217 neurology & neurosurgery Dyslipidemia medicine.drug Lipoprotein |
| Zdroj: | Biologicalpharmaceutical bulletin. 41(12) |
| ISSN: | 1347-5215 |
| Popis: | Melatonin has been suggested to play important roles in lipid metabolism as well as circadian rhythm; however, very few studies explored the effects of ramelteon, a selective melatonin receptor agonist, on serum lipid profiles. In this study effects of ramelteon on serum lipid profiles were explored, comparing to those of other sleep-promoting drugs including benzodiazepines and non-benzodiazepines, in patients with insomnia. We retrospectively reviewed medical charts of outpatients who were treated with ramelteon (8 mg/d) or other sleep-promoting drugs for no less than 8 weeks during the period between October 1st, 2011 and September 30th, 2014, and compared the changes in serum lipid profiles between the two groups. Patients with regular dialysis or malignant diseases treated with cytotoxic anti-cancer drugs, or whose lipid-lowering drugs were altered during the study period, were excluded. Among 365 or 855 outpatients treated with ramelteon or other sleep-promoting drugs, 35 or 46 patients, respectively, had complete serum low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C) data. Serum LDL-C was significantly reduced from 103.1±4.4 to 94.6±4.2 mg/dL (8.2% reduction, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|